Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D39TVC
|
|||
| Drug Name |
Tinostamustine
|
|||
| Synonyms |
Tinostamustine; EDO-S101; 1236199-60-2; EDO-S 101; EDO-S-101; Tinostamustine [USAN]; Tinostamustine(EDO-S101); 29DKI2H2NY; 7-(5-(bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)-N-hydroxyheptanamide; 1H-Benzimidazole-2-heptanamide, 5-[bis(2-chloroethyl)amino]-N-hydroxy-1-methyl-; 7-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-N-hydroxyheptanamide; Minomustine; 1H-Benzimidazole-2-heptanamide, 5-(bis(2-chloroethyl)amino)-N-hydroxy-1-methyl-; starbld0018955; UNII-29DKI2H2NY; Tinostamustine (USAN/INN); TINOSTAMUSTINE [INN]; SCHEMBL7915449; TINOSTAMUSTINE [WHO-DD]; CHEMBL3989941; BCP20331; EX-A1322; BDBM50569838; AKOS030526024; CS-6484; DB15147; SB19172; BE170657; MS-27198; HY-101780; S8769; D11182; E76854; 7-{5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}-N-hydroxyheptanamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 1/2 | [1] | |
| Company |
Mundipharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H28Cl2N4O2
|
|||
| Canonical SMILES |
CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCCCCC(=O)NO
|
|||
| InChI |
InChI=1S/C19H28Cl2N4O2/c1-24-17-9-8-15(25(12-10-20)13-11-21)14-16(17)22-18(24)6-4-2-3-5-7-19(26)23-27/h8-9,14,27H,2-7,10-13H2,1H3,(H,23,26)
|
|||
| InChIKey |
GISXTRIGVCKQBX-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histone deacetylase (HDAC) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03687125) Phase 1/2 Open-label Trial of Tinostamustine Conditioning and Autologous Stem Cell Transplantation for Salvage Treatment in Relapsed / Refractory Multiple Myeloma (TITANIUM 1). U.S.National Institutes of Health. | |||
| REF 2 | The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. J Hematol Oncol. 2018 Feb 27;11(1):32. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.